283 related articles for article (PubMed ID: 35748543)
21. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
Phuengkham H; Ren L; Shin IW; Lim YT
Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
[TBL] [Abstract][Full Text] [Related]
22. Nanomaterials: small particles show huge possibilities for cancer immunotherapy.
Chen Z; Yue Z; Yang K; Li S
J Nanobiotechnology; 2022 Nov; 20(1):484. PubMed ID: 36384524
[TBL] [Abstract][Full Text] [Related]
23. Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy.
Vincent MP; Navidzadeh JO; Bobbala S; Scott EA
Cancer Cell; 2022 Mar; 40(3):255-276. PubMed ID: 35148814
[TBL] [Abstract][Full Text] [Related]
24. Self-assembling peptides-based nano-cargos for targeted chemotherapy and immunotherapy of tumors: recent developments, challenges, and future perspectives.
Wang XJ; Cheng J; Zhang LY; Zhang JG
Drug Deliv; 2022 Dec; 29(1):1184-1200. PubMed ID: 35403517
[TBL] [Abstract][Full Text] [Related]
25. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
26. Nanoenabled Tumor Oxygenation Strategies for Overcoming Hypoxia-Associated Immunosuppression.
Zhang C; Yan Q; Li J; Zhu Y; Zhang Y
ACS Appl Bio Mater; 2021 Jan; 4(1):277-294. PubMed ID: 35014284
[TBL] [Abstract][Full Text] [Related]
27. Augmenting the synergies of chemotherapy and immunotherapy through drug delivery.
Kim J; Manspeaker MP; Thomas SN
Acta Biomater; 2019 Apr; 88():1-14. PubMed ID: 30769136
[TBL] [Abstract][Full Text] [Related]
28. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
[TBL] [Abstract][Full Text] [Related]
29. Stimuli-Responsive Polymeric Nanomaterials for the Delivery of Immunotherapy Moieties: Antigens, Adjuvants and Agonists.
Nagareddy R; Thomas RG; Jeong YY
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830392
[TBL] [Abstract][Full Text] [Related]
30. Peptide-Based Nanomaterials for Tumor Immunotherapy.
Li L; Ma B; Wang W
Molecules; 2020 Dec; 26(1):. PubMed ID: 33396754
[TBL] [Abstract][Full Text] [Related]
31. Advances of functional nanomaterials for cancer immunotherapeutic applications.
Hao Y; Zhou X; Li R; Song Z; Min Y
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1574. PubMed ID: 31566896
[TBL] [Abstract][Full Text] [Related]
32. Using functional nanomaterials to target and regulate the tumor microenvironment: diagnostic and therapeutic applications.
Ji T; Zhao Y; Ding Y; Nie G
Adv Mater; 2013 Jul; 25(26):3508-25. PubMed ID: 23703805
[TBL] [Abstract][Full Text] [Related]
33. Carbon-Based Nanomaterials for Cancer Therapy via Targeting Tumor Microenvironment.
Saleem J; Wang L; Chen C
Adv Healthc Mater; 2018 Oct; 7(20):e1800525. PubMed ID: 30073803
[TBL] [Abstract][Full Text] [Related]
34. Nanomaterials: A powerful tool for tumor immunotherapy.
Chen Z; Yue Z; Wang R; Yang K; Li S
Front Immunol; 2022; 13():979469. PubMed ID: 36072591
[TBL] [Abstract][Full Text] [Related]
35. Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade.
Zhou F; Feng B; Yu H; Wang D; Wang T; Ma Y; Wang S; Li Y
Adv Mater; 2019 Apr; 31(14):e1805888. PubMed ID: 30762908
[TBL] [Abstract][Full Text] [Related]
36. [Development and application of adjuvant immunotherapy for cancer].
Kitahata Y; Ishii KJ
Nihon Rinsho; 2017 Feb; 75(2):329-333. PubMed ID: 30562873
[TBL] [Abstract][Full Text] [Related]
37. An overview of biodegradable nanomaterials and applications in vaccines.
Yan X; Zhou M; Yu S; Jin Z; Zhao K
Vaccine; 2020 Jan; 38(5):1096-1104. PubMed ID: 31813649
[TBL] [Abstract][Full Text] [Related]
38. [Strategies and challenges of immunotherapy for hepatocellular carcinoma].
Zhang HH; Chen HS
Zhonghua Gan Zang Bing Za Zhi; 2020 Jun; 28(6):457-460. PubMed ID: 32660170
[TBL] [Abstract][Full Text] [Related]
39. Current challenges for cancer vaccine adjuvant development.
Bowen WS; Svrivastava AK; Batra L; Barsoumian H; Shirwan H
Expert Rev Vaccines; 2018 Mar; 17(3):207-215. PubMed ID: 29372660
[TBL] [Abstract][Full Text] [Related]
40. Emerging strategies in developing multifunctional nanomaterials for cancer nanotheranostics.
Ang MJY; Chan SY; Goh YY; Luo Z; Lau JW; Liu X
Adv Drug Deliv Rev; 2021 Nov; 178():113907. PubMed ID: 34371084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
